NEJM publishes Bizengri data after speedy FDA nod

The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus (Nasdaq: MRUS).

Bizengri is the first approved treatment for people with advanced non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma, driven by NRG1 gene fusion.

Details from the study show an overall response rate of 33% in NSCLC patients and 40% in those with pancreatic cancer. The findings reinforce the therapy’s role in targeting a rare genetic driver of cancer that has historically lacked effective treatment options.